title: Docosahexaenoic- and eicosapentaenoic acid-bound lysophospholipids are more effective in suppressing angiogenesis than conjugated docosahexaenoic acid.
abstract: Suppression of leukemia, colon cancer, myeloma, and fibrosarcoma to some extent by omega 3 fatty acid bound phospholipids has been reported in the last two decade. However, the anti-angiogenic activity of those phospholipids is still not known. Four kinds of marine phospholipid molecular species i.e. starfish EPA bound diacyl phospholipid (EPA-PC), EPA bound monoacyl phospholipid (EPA-LPC) which was prepare via Lipozyme RMIM mediated partial hydrolysis of EPA-PC, squid DHA bound diacyl phospholipid (DHA-PC), and DHA bound monoacyl phospholipid (DHA-LPC) which was also prepare via Lipozyme RMIM mediated partial hydrolysis of DHA-PC, were subjected to antiangiogenic activity assay by using a piece of rat main artery and a human umbilical cord vein endothelial cell. The lengths of micro vein generated from those tissues after incubation with the above four kinds of phospholipid molecular species were measured and compared. EPA-LPC and DHA-LPC showed strong antiangiogenic activity on the rat main artery tissue, while on the human umbilical cord vein endothelial cells, 100 µM of EPA-LPC in the culture medium, exhibited the most effective suppression on angiogenesis, followed by 100 µM of DHA-LPC. It was concluded that EPA-LPC obtained via Lipozyme RMIM mediated partial hydrolysis of EPA-PC is the most effective omega 3 phospholipid on anti-angiogenesis.
authors.affiliation: Faculty of Fisheries Sciences, Hokkaido University, 3-1-1 Minato-cho, Hakodate, Hokkaido 041-8611, Japan. tadahiro1026@yahoo.co.jp
authors.forename: Tadahiro
authors.initials: T
authors.lastname: Tsushima
authors.forename: Kiminori
authors.initials: K
authors.lastname: Matsubara
authors.forename: Takeshi
authors.initials: T
authors.lastname: Ohkubo
authors.forename: Yoshikazu
authors.initials: Y
authors.lastname: Inoue
authors.forename: Koretaro
authors.initials: K
authors.lastname: Takahashi
mesh_terms: D000818:Animals; D001011:Aorta / Q000187:drug effects; D002465:Cell Movement / Q000187:drug effects; D049832:Decapodiformes; D004281:Docosahexaenoic Acids / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use*; D015118:Eicosapentaenoic Acid / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use*; D061307:Human Umbilical Vein Endothelial Cells / Q000166:cytology / Q000187:drug effects; D006801:Humans; D066298:In Vitro Techniques; D008244:Lysophosphatidylcholines / Q000494:pharmacology / Q000627:therapeutic use; D008246:Lysophospholipids / Q000494:pharmacology / Q000627:therapeutic use*; D008297:Male; D009389:Neovascularization, Pathologic / Q000188:drug therapy*; D018919:Neovascularization, Physiologic / Q000187:drug effects; D010713:Phosphatidylcholines / Q000494:pharmacology / Q000627:therapeutic use; D051381:Rats; D017208:Rats, Wistar; D034421:Sus scrofa
chemical_list: D008244:Lysophosphatidylcholines; D008246:Lysophospholipids; D010713:Phosphatidylcholines; D004281:Docosahexaenoic Acids; D015118:Eicosapentaenoic Acid